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Human monoclonal antibody fragments neutralizing wild-type and vaccine strains of yellow fever (YF) virus (genotypes West
Africa I + II, East/Central Africa, 17D-204-WHO) were generated by repertoire cloning from YF patients. Analysis of virus escape
variants identified amino acid (aa) 71 in domain II of the envelope glycoprotein (E) as the most critical residue for neutralization,
with aa 153–155 in domain I contributing to the epitope. These data confirm the previous mapping of YFV neutralizing epitopes
using mouse monoclonal antibodies but suggest that a conformational epitope could be formed by amino acids from domains I
and II opposing each other in the dimeric form of the E protein. While the sera of the YF patients showed up to 10-fold reduced
neutralizing activity against the 17D escape variants, sera from 17D vaccinees retained their neutralizing titers. Mutations in this
major neutralizing epitope of YFV thus do not seem to carry the risk of immune escape in persons immunized with the YFV-17D
vaccine.
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Yellow fever virus (YFV) is an important human
pathogen, causing an estimated number of 200,000
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Infectious Diseases, Leiden University Medical Center, Leiden, The
Netherlands.Africa and South America annually (Robertson et al.,
1996). The spectrum of disease ranges from flu-like
symptoms to fulminant hemorrhagic fever with multiorgan
failure (Monath and Barrett, 2003). A live-attenuated
vaccine (YFV strain 17D and related substrains), which
induces humoral immunity against the currently known six
genotypes of YFV, was developed in the 1930s through
serial passage of wild-type YFV on different cell substrates
(Monath, 2004). Neutralizing antibodies are predominantly
directed against the envelope glycoprotein E of the virus
(Brandriss et al., 1986; Gould et al., 1986; Pincus et al.,
1992), which for other flaviviruses has been shown to
govern the host cell receptor binding and endosomal pH-
dependent membrane fusion (Lindenbach and Rice, 2001).
Discrete neutralizing epitopes involving the envelope05) 262 – 272
S. Daffis et al. / Virology 337 (2005) 262–272 263protein amino acids (aa) E-71, E-72, E-155, E-158, E-173,
E-240, E-305 and E-325 have been mapped on the
monomeric E protein using mouse monoclonal antibodies,
but no molecular studies of human antibody responses to
YFV have been performed to date (Lobigs et al., 1987;
Ryman et al., 1997a, 1997b, 1998).
The 17D vaccine is regarded as very safe and highly
effective; however, serious and potentially fatal side-
effects have recently been reported mainly in elderly
persons (Kitchener, 2004; Lawrence et al., 2004; Martin
et al., 2001). Because the currently used 17D vaccines
essentially constitute quasi-species of closely related viral
variants and the neutralizing epitopes of YFV have not
been mapped for humans, it cannot be ruled out that
naturally occurring neutralization escape variants might
be present in 17D vaccine preparations (Pugachev et al.,
2002). To gain insight into this problem, we mapped the
neutralizing epitopes of the YFV-E protein using human
monoclonal antibody fragments derived from yellow fever
patients and generated neutralization escape variants of
the 17D-204 vaccine strain. The rationale for screening
patient immune libraries with the vaccine virus (as
opposed to the homologous wild-type virus) was to
identify yellow fever type-specific epitopes; furthermore,
17D yellow fever virus antigen can be handled without
chemical or physical inactivation under biosafety level 2
conditions, thus sensitive conformational epitopes are not
denatured.Fig. 1. Alignment of the variable heavy (VH) and the variable light chains (V
complementarity-determining regions (CDR) are indicated in bold. The closest
www.ncbi.nlm.nih.gov/igblast/).Results
Generation of antibody phage display libraries and
selection of antibody fragments reactive with YFV
Two antibody-phage libraries (size 8  106 and 7  107
clones, respectively; >75% correct single-chain antibody
inserts) were constructed by repertoire cloning from yellow
fever patients, subsequently pooled and panned with
glycerol-purified non-inactivated YFV-17D virions. 50
monoclonal phage clones from selection rounds 3 and 4
showed specific binding to the YFV antigen in ELISA (data
not shown). BstN1 fingerprinting revealed six distinct
restriction patterns (data not shown); all clones representa-
tive of each pattern showed strong binding to YFV but not
to BSA (data not shown). Sequencing of the single-chain
antibodies (scFv) revealed usage of only two different VH
genes, most closely related to germline genes VH4-59 and
VH3-11, and three different VL genes, related to germline
genes VnL-12, VL1-19 and VL2-14 (Fig. 1). All comple-
mentarity determining regions (CDR) of the VH domains of
scFv-5A, 7A and R3(27) were identical; the few differences
observed in framework 1 (FR1) and FR4 are probably due
to the usage of degenerated primers for PCR amplification.
The VL domains of these three antibodies were similar,
differing mainly in the CDR2 and CDR3 regions. The VH
domains of scFv-1A, 2A and R3(9) were also identical, but
only two of the VL domains were similar, with substitutionsL) of scFv reactive with YFV in ELISA. Framework regions (FR) and
germline V-gene for each chain was identified using IgBLAST (http://
S. Daffis et al. / Virology 337 (2005) 262–272264located in CDR2 and CDR3 (GenBank accession nos. for
the scFv: AY661699, AY661700,AY661701, AY661702,
AY661703 and AY661704).
Genotyping of wild-type YFV strains used in the study
The strains Central African Republic (CAR) 1986 and
Ethiopia 1961 were found to belong to the genotype East
Africa/Central Africa (EA/CA) and the strain Senegal
1990 to the genotype West Africa II (WAII). The Nigeria
1987 and Ghana 1927 (Asibi) strains have been previ-
ously identified by Mutebi et al. (2001) as belonging to
West Africa I (WA I) and West Africa II (WA II),
respectively (GenBank accession nos. for the E sequences:
AY839634, AY839635 and AY839636). In 2000, a single
strain of YFV caused the yellow fever epidemic in Guinea,
West Africa, during which the two patients of this study
were identified (ter Meulen et al., 2004). The envelope
sequence of this YFV was identical to that of the Asibi
strain, with the exception of an N450S mutation
(AY502949).
Soluble scFv neutralize YFV-Asibi, YFV-17D and wild-type
YFV strains of genotypes West Africa I and II and East/
Central Africa
As shown in Fig. 2, the three closely related scFv-5A,
7A and R3(27) showed 50% and 100% neutralizing activity
in plaque reduction neutralization assay (PRNT) against
YFV strains 17D-204-WHO (A) and Asibi (B) at concen-
trations of approximately 1 Ag/ml and 10 Ag/ml, respec-
tively, whereas the three other scFv did not neutralize at
any concentration tested. YFV type-specific mAbs 6538
and 6330 directed against the E protein were used as
controls (Gelderblom et al., 1985). An irrelevant scFvFig. 2. Neutralization of the 17D-204-WHO (A) and the Asibi (B) strain of YFV by
specific mAbs 6538 and 6330 were used as positive controls. As a negative contisolated from the same library was included as negative
control. Fig. 3 shows that scFv-5A, 7A and R3(27)
neutralized wild-type YFV strains of genotypes West Africa
I (Nigeria 1987) and II (Asibi) and East/Central Africa
(CAR 1986, Ethiopia 1961) with comparable efficiency in
a PRNT on PS cells. The concentration of scFv required for
90% plaque reduction ranged from 0.1 to 3.0 Ag/ml of
antibody fragment, with scFv-5A showing the highest
potency. Interestingly, the strain Senegal 1990 was neutral-
ized four to 10-fold less efficiently than all other strains.
This strain was found to differ from Asibi by an N153K
mutation and three additional mutations (T7A, A54V,
N249D) in the envelope, two of which are located in the
vicinity of the amino acids forming the neutralizing epitope
(see below, and Fig. 7). Of the second group of closely
related antibody fragments, only scFv-R3(9) showed some
activity, neutralizing the YFV strain Nigeria 87 to
maximally 60%. The envelope gene of this strain is
identical to Asibi, with the exception of the mutations
F426L and V430I. No scFv neutralized a West Nile virus
strain isolated in France in 2000.
All neutralizing scFv bind to the same or closely related
conformational epitope on the E protein
To identify the proteins recognized by the neutralizing
scFv, an immunoprecipitation assay with radiolabeled,
purified YFV-17D virions was performed. All scFv as
well as the two envelope-specific mouse mAbs were found
to precipitate a 55-kDa protein, corresponding to the
molecular weight of the envelope glycoprotein (Fig. 4B).
MAb 6330 but not mAb 6538 and none of the scFv
reacted with a band of the same molecular weight in
Western blot (Fig. 4A). This 55-kDa band was not
precipitated by an irrelevant scFv from the same libraryscFv in plaque reduction neutralization test (PRNT) using Vero cells. YFV-
rol, an irrelevant scFv from the same library was used.
Fig. 3. Neutralization of wild-type strains of YFV by scFv-5A (A), scFv-7A (B), scFv-R3(27) (C) and scFv-R3(9) (D) in PRNT using PS cells. As a negative
control, an irrelevant scFv from the same library was used.
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antibody alone. In a competition ELISA using biotinylated
scFv-7A, this antibody fragment competed for binding to
YFV-17D virions with the other neutralizing antibody
fragments 5A, R3(27) and R3(9), but not with the non-
neutralizing scFv-1A and 2A (Fig. 5). It can thus be
concluded that all neutralizing scFv bind to the same or
closely related conformational epitope on the envelope
protein.Fig. 4. Reactivity of scFv with YF-E protein. (A) Analysis of scFv reactivity in Wes
against purified YFV virions. (B) Immunoprecipitation of radiolabeled soluble
precipitated with each scFV. YFV-E-specific mAbs 6538 and 6330 were used as
library and an anti His-tag antibody were used.The amino acids critical for neutralization are located in
domains I and II of the E protein and oppose each other in
the dimeric form of the molecule
Four YFV-17D-204-WHO variants resistant to neutrali-
zation with scFv-7Awere generated (Fig. 6). Mutants 7A-14
and 7A-18 showed low neutralization resistance (75%
neutralization) and 7A-10 intermediate resistance (50%
neutralization). The fourth mutant, 7A-12, was almosttern Blot. All scFvs and two mAbs were tested separately for their reactivity
YF viral proteins. Radiolabeled soluble YFV-E proteins were immuno-
positive controls. As negative controls, an irrelevant scFv from the same
Fig. 6. Neutralization sensitivity of YFV-17D escape mutants to scFv-7A.
The scFv-7A-neutralization resistance of four escape mutants (7A-10, 7A-
12, 7A-14 and 7A-18) which were selected in the presence of subneutraliz-
ing concentrations of scFv-7A was tested in PRNT using various
concentrations of scFv-7A. As a positive control, the parental YFV-17D-
204-WHO virus was used.
Fig. 5. Competition of scFv or E-specific mAbs for binding to YFV 17D-
204-WHO virions using biotinylated scFv-7A. Unlabeled scFv or mAbs
were used as competitor.
S. Daffis et al. / Virology 337 (2005) 262–272266completely resistant to neutralization by scFv-7A (max. 5%
neutralization). The sequence of the complete membrane
and envelope genes of all escape variants and the parental
17D strain revealed mutations only in the E protein gene
(Table 1). A total of four amino acid changes were
identified: N71K in domain II (escape variant 7A-12),
T153A in domain I (variant 7A-18), T153A and T154A
(variant 7A-14) and D155G (variant 7A-10). The mutation
at E-71 conferred the highest neutralization resistance.
The published crystal structure of the closely related
dengue virus type 2 glycoprotein E was used to model the
structure of the YFV-E protein and locate the escape
mutations. As shown in Fig. 7, all mutations are exposed
on the surface of the YFV E protein; however, because of
spatial separation, domains I and II are unlikely to
participate in forming an epitope in the monomeric E
protein. However, in the homodimeric, antiparallel orienta-
tion which the molecules are predicted to adopt on the
surface of the virion, the domain I and II from two E
proteins are closely opposing each other (distance 15–20
A˚). It is thus possible that the neutralizing epitope is formed
by two E proteins, which each contribute a different
domain.
YFV-17D escape variants generated with scFv-7A are
efficiently neutralized by sera of YFV-17D vaccinees
To evaluate the importance of mutations in aa E-71 and
E-155 with respect to neutralization escape of YFV-17D
virus variants in human polyclonal sera, microneutralization
assays were performed using sera from West African yellow
fever patients and sera of travelers who had received routine
YFV-17D immunization. Fig. 8 shows the 50% end-point
dilution (NT50) of the sera of two yellow fever patients (sera
A) and eight 17D vaccinees (sera B) with YFV-17D-204-WHO and the derived neutralization resistant variants 7A-
12 (N71K) and 7A-10 (D155G). Both sera of the yellow
fever patients neutralized 7A-12 up to 10-fold less
effectively compared to the parental 17D-204-WHO strain,
whereas the sera of the immunized travelers showed
unchanged or only slightly reduced neutralizing activity
against 7A-12. Paradoxically, the neutralizing titers of most
sera against the escape variant 7A-10 were significantly
higher (up to 10-fold) compared with their titers against the
parental 17D virus.Discussion
Yellow fever virus neutralizing antibodies are predomi-
nantly directed against the envelope glycoprotein E, the
crystal structure of which has been solved for the related
flavivirus tick borne encephalitis (TBE) virus and dengue
virus (Kuhn et al., 2002; Rey et al., 1995). Because of a high
degree of sequence similarity and conservation of all
cysteine residues, it is assumed that the E proteins of all
flaviviruses share a common three-dimensional structure.
The ectodomain of the E protein folds into three distinct
domains, a central domain (I), a dimerization and fusion
domain (II) and an IgG-like domain responsible for
interaction with the unknown cellular receptor (III).
Mapping of neutralizing epitopes on the YFV-E protein
using mouse monoclonal antibodies has previously revealed
critical amino acid residues in domain II (aa E-71/72, E-
173), domain III (E-305/325) and domain I (aa E-155/158)
(Lobigs et al., 1987; Ryman et al., 1997a, 1997b, 1998).
To define the human immune response to YFV on the
epitope level, we generated human monoclonal antibody
Table 1
Nucleotide and amino acid differences in the E protein between YFV-17D-204-WHO virus and scFv-7A escape mutants
Escape variants nt changesa aa changesa E protein domain Percentage of neutralization
by scFv 7Ab
Published aac
7A-14 nt 1430 A-G E153 T-A I 75% Td, Ne, Kf
nt 1433 A-G E154 T-A I Tg, Ah
7A-10 nt 1437 A-G E155 D-G I 50% Di, Sj, Gk, Al
7A-18 nt 1430 A-G E153 T-A I 75% see above
7A-12 nt 1186 T-G E71 N-K II 5% Dm, Kn, Ho, Yp
a Compared to the parental 17D-204-WHO strain.
b Plaque reduction neutralization tests performed with 10 Ag/ml purified soluble single-chain Fv fragments.
c Amino acid published for positions E-71, E-153, E154 and E-155 in wild-type YFV, vaccine strains, escape variants or adapted strains.
d In vaccine strains 17D-204-WHO (Jennings et al., 1993), 17D-213-WHO (GenBank accession #AAC54268) and 17D-204-USA (#AAC35899).
e In vaccine strains 17D-204-Pasteur (#P19901), 17D-204-ATCC, 17DD from Brazil (#U17066) and Senegal (Jennings et al., 1993) and in all wild-type YFV
strains.
f In the French neurotropic virus (#U21055) and a YFV strain isolated from mosquitoes in Trinidad (#U23568).
g In all YFV strains except footnote h.
h In three South American YFV strains isolated from humans (#U23566, #U23565 and #P29165).
i In all YFV strains except footnotes j, k, l.
j In 17DD from Brazil and Senegal.
k In a 17D-204-WHO escape variant (Ryman et al., 1997a) and in a fatal case of post-vaccinal encephalitis (Jennings et al., 1994).
l In Asibi virus adapted to Hela-cells (Dunster et al., 1999) and to Syrian hamster (McArthur et al., 2003).
m In a YFV strain isolated from mosquitoes in Trinidad (same isolate as in footnote f).
n In 17D-204-ATCC escape variants (Lobigs et al., 1987).
o In 17D-204-ATCC escape variants (Lobigs et al., 1987).
p In 17D-204-ATCC escape variants (Lobigs et al., 1987).
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yellow fever patients and screened the libraries with a
vaccine strain of YFV. Three of the four neutralizing single-
chain antibody fragments isolated had almost identical VH
and very similar VL regions and all four competed for the
same conformational epitope on the envelope glycoprotein.
This epitope was mapped to a critical amino acid in domain
II (E-71), with several amino acids in domain I contributing
to a lesser extent to neutralization (E-153, E-154, E-155).
No mutations were identified in domain III, which is
responsible for attachment of the virus to the cellular
receptor. Based on modeling of the sequence of the yellow
fever E protein on the structure of the dengue virus type 2
envelope protein (Fig. 7), aa E-71 and E-155 are spatially
separated by 65–70 A˚ in the monomeric protein. This
distance is far beyond the surface area which the VH and VL
chain of a single-chain antibody fragment can cover, ranging
typically from 15 A˚  20 A˚ to 20 A˚  30 A˚ (Davies and
Padlan, 1990). However, in the homodimeric form of the
molecule, domains I and II of opposing monomers are
predicted to be in close vicinity with a separating distance of
15–20 A˚ between aa E-71 and E-155 (Fig. 7). Furthermore,
we identified naturally occurring mutations in close vicinity
to E-71 (i.e., E-249) and E-153 (i.e., E-7) in the wild-type
yellow fever strain Senegal 1990, which also displayed a
T153K mutation (Fig. 7). This virus strain was 5–10 times
less sensitive to neutralization by the monoclonal antibody
fragments compared to the other yellow fever strains tested
(Fig. 3). Thus, the data can be reconciled by assuming that
the antibodies bind to an epitope on the tip of the dimer,
formed by amino acids from domains I and II of opposing
chains (Fig. 7). Very similar to this finding, the conforma-tional epitope of a chimpanzee derived monoclonal anti-
body which cross-neutralized dengue virus serotypes 1–4
and West Nile virus was recently shown to be defined by aa
E-106 at the tip of domain II and E-137 in domain III of
opposing E molecules (Goncalvez et al., 2004).
E-71 is the most critical amino acid of the identified
YFV type-specific neutralizing epitope, because a muta-
tion at this position conferred much higher resistance to
neutralization with scFv-7A than mutations at E-153, E-
154 or E-155 (95% vs. 25–50% in PRNT, respectively).
A review of the literature for variability occurring in this
region revealed that the Asn residue at position E-71 and
Gln residue at position E-72 are 100% conserved among
all wild-type and vaccine strains of YFV published to
date, with the exception of one YFV strain isolated from
mosquitoes in 1979 in Trinidad (Table 1). In contrast, the
Thr at position E-153 and E-154 shows variation both in
vaccine strains and in wild-type isolates (Table 1). A
potential N-linked glycosylation site in the E protein of
flaviviruses is located at aa E-151 to E-153, which is
utilized by the 17DD and 17D-213 vaccine strains (Post
et al., 1991), whereas neither of the wild-type strains of
this study has a glycosylation site at this position (aa N-W-
N/K at positions E-151 to E-153). Because the 17D-204-
WHO vaccine strain used in this study displays N151,
W152 and T153, the escape variants 7A-14 and 7A-18
could be glycosylation mutants (Table 1). The T154A
mutation in virus variant 7A-14 has previously not been
reported as a neutralization escape but was found in
human wild-type YFV isolates from Ecuador and Peru
(Table 1). Interestingly, the D155G mutation of our escape















Fig. 7. Locations of residues E-71 and E-153, E-154, E-155 associated with neutralization escape, and naturally occurring mutations in the E protein of YFV
strain Senegal 1990 (E-7, E-54, E-153 and E-249). The sequence of YFV-E was modeled on the 3D structure of the dengue virus type 2 envelope glycoprotein
using RasMol (www.umass.edu/microbio/rasmol). (A) Top view of the E protein homodimer with domains I, II and III indicated. (B) Side view.
S. Daffis et al. / Virology 337 (2005) 262–272268mutation in a 17D virus variant isolated from a human
case of vaccine associated encephalitis (Jennings et al.,
1994). The 17DD vaccine strains from Brazil and
Senegal, which showed slightly increased neurovirulence
in animal models (Barrett and Gould, 1986), both have a
D155S substitution (Table 1).
The only neutralizing antibody specificity isolated from
YF patients in this study was directed against one epitope
located in domain II of the E protein of a YFV 17D vaccine
virus. This is in line with observations that cross-reactive
flavivirus antibodies are mostly directed against domain II,
whereas strain-specific antibodies are directed against
domain III of the envelope protein (Crill and Chang,
2004, Roehrig, 2003). However, it cannot be excluded thatthe antibody repertoire was restricted in the severely ill YF
patients from which the libraries were derived. Whether we
identified the major epitope by which 17D vaccine strains
induce humoral immunity against wild-type YFV infection
therefore needs to be tested in vivo in a relevant animal
model.
We further investigated the capacity of polyclonal sera
from yellow fever cases and immunized travelers to
neutralize the two YFV-17D-derived escape variants with
mutations N71K and D155G, respectively. The neutralizing
titers of the YF patients were up to 10-fold reduced with the
N71K variant, confirming the importance of E-71 for
neutralization (Fig. 8). In contrast, the neutralizing titers
of the vaccinees remained unchanged or were only slightly
Fig. 8. Sensitivity of escape mutants 7A-10 and 7A-12 to neutralization by sera from YF patients (sera A) and from 17D vaccinees (sera B). As a positive
control, the parental YFV-17D-204-WHO virus was used. 50% endpoint dilution represents the dilution of each serum at which 50% of the wells were
protected from infection and is indicated as reciprocal dilution in a log10 scale. Each serum was tested in five replicates.
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50% neutralization resistance to the monoclonal antibody
fragment) showed approximately 10-fold increased sensi-
tivity to neutralization with half of the human sera. A
possible explanation could be that the D155G mutation
results in conformational changes in the envelope leading to
exposure of other neutralizing epitopes.
Taken together, these in vitro data suggest that mutations
in the E-71/E-153/E-154/E-155 epitope of wild-type or
vaccine strains of YFV do not carry a risk of neutralization
escape in persons immunized with the 17D vaccine.Materials and methods
Virus strains
A commercially available preparation of the 17D-204-
WHO yellow fever virus vaccine, manufactured by the
Robert Koch Institute, Berlin, Germany, was used for the
production of antigen and generation of neutralization
escape variants. Wild-type yellow fever strains Asibi (Ghana
1927), ArD76320 (Senegal 1990), BA-55 (Nigeria 1987),
ETH2777 (Ethiopia 1961) and HB1782 (CAR 1986) were
obtained as lyophilized stocks made on suckling mouse
brain; in addition, cell culture supernatant of a West Nile
virus strain isolated in 2000 in France was used. Vero cells
(ATCC-LGC) were grown in DMEM supplemented with
10% FCS, 2 mM glutamine and penicillin–streptomycin
at 37 8C in a 5% CO2 humidified atmosphere. Cells were
infected with a 1:10 dilution of the virus stocks and the
supernatants were titrated on day 5 post-infection in a
plaque assay. For virus neutralization assays, porcine
kidney PS cells were grown in Leibovitz 15 medium
(L-15) containing 5% FCS and penicillin–streptomycin at
37 8C in non-CO2 humidified atmosphere.Purification of YFV-17D, strain 204-WHO virions
Subconfluent Vero cells grown in T225 flask were
infected with YFV-17D at a multiplicity of infection (moi)
of 0.1 for 5 days at 37 8C. YFV-17D particles contained in
the supernatant were purified by centrifugation at
70,000g for 2 h at 4 8C through a 30% (v/v) glycerol/
PBS cushion in a Beckmann SW28 rotor. Pelleted virions
were resuspended in TNE buffer (10 mM Tris–HCl pH
7.5, 150 mM NaCl, 5 mM EDTA) and proteins were
quantified using the BCA assay kit (Pierce Biotechnology,
Rockford, IL, USA). Purity of the virus preparation was
analyzed by SDS–PAGE.
Construction of antibody phage display libraries
Two phage libraries displaying single-chain antibodies
(scFv) were constructed as previously described (Konter-
mann, 2001). Briefly, peripheral blood lymphocytes were
prepared from two severely ill, but fully recovered yellow
fever patients approximately 6 months after the acute
infection. The patients had been identified during a yellow
fever epidemic in 2000 in Guinea, West Africa (ter Meulen
et al., 2004). Their YFV neutralizing antibody titers at the
time of PBL donation were determined as 1:2560 by virus
neutralization assay. Total RNA was extracted from >107
PBL (RNeasy kit, QIAGEN, Hilden, Germany) and
mRNA was reverse transcribed into cDNA using random
hexamer primers. Variable heavy and light chain genes
were amplified from cDNA by a two-step nested PCR
using a combination of 38 degenerated primers (Marks et
al., 1991). The PCR-amplified n and k fragments were
pooled, digested with ApaLI and NotI, and ligated to the
phagemid vector pHEN3 (Korn et al., 2004). Electro-
competent TG1 Escherichia coli cells (Stratagene, La
Jolla, CA, USA) were transformed with the ligation
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(VLn) and a variable k light chain (VLk) pHEN3 sub-
library, respectively. Phagemid DNA from these two sub-
libraries was digested with SfiI and XhoI and ligated to
PCR-amplified variable heavy (VH) fragments. The ligated
products were electroporated into TG1 cells and expanded
to obtain a (VH-VLn)-pHEN3 and a (VH-VLk)-pHEN3
library. These VH-VLn and VH-VLk libraries were infected
with helper phages and the rescued recombinant phages
were precipitated from cell culture supernatants with 20%
PEG6000/2.5 M NaCl and resuspended in PBS for
subsequent panning.
Selection of YFV-binding antibody phage clones by panning
The two phage libraries were pooled and then panned
with glycerol-purified YFV-17D particles essentially as
described (Kontermann, 2001). Briefly, 1013 phage units
from each library were panned in immunotubes (Maxisorp,
Nunc, Wiesbaden, Germany) coated overnight with purified
non-inactivated YFV-17D-204-WHO particles (25 Ag/ml in
0.05 M carbonate buffer pH 9.6). Immunotubes were
washed with PBS/0.1% Tween-20 and PBS. Bound phages
were eluted with 0.1 M triethylamine and used to infect a
fresh log-phase TG1 culture. For the identification of YFV-
specific monoclonal phages, single TG1 colonies obtained
from the third and the fourth round of selection were
screened for binding. Bacteria grown in 96-well microtiter
plates were infected with helper phages and grown
overnight to allow the rescue of monoclonal phages.
Supernatants containing monoclonal phages were tested in
ELISA and phages bound to YFV were detected using an
anti-M13 horseradish peroxidase-conjugated antibody
(Pharmacia, Freiburg, Germany) diluted 1:5000. Diversity
of clones was analyzed by BstN1 fingerprinting and DNA
of single clones was sequenced with primers fdseq1 and
LMB3 (Kontermann, 2001).
Production and purification of soluble scFvs
For soluble expression, scFv fragments were subcloned
into the pAB1 plasmid. This vector introduces a His-tag in
the C-terminus of the scFv and allows inducible expression
in the periplasmic space of E. coli TG1 cells (Kontermann et
al., 1997). ScFv fragments were purified from periplasmic
preparations by immobilized metal affinity chromatography
(IMAC) as described.
Single-chain antibody (scFv) ELISA
Microtiter wells were coated with glycerol-purified
YFV-17D particles at a concentration of 25 Ag/ml in 0.05
M carbonate buffer pH 9.6. After blocking with PBS/2%
skimmed milk, the purified scFv were added and
incubated for 1 h at room temperature. Bound scFvs
were detected by incubation with a murine anti-His-tagantibody (Santa Cruz Biotechnology, Santa Cruz CA,
USA) and horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (Dako, Hamburg, Germany),
both diluted 1:1000. ABTS (KPL, Gaithersburg, USA),
was used as substrate and absorbance was measured at
405 nm.
Production of radiolabeled YFV virions and
immunoprecipitation (IP) assay
A T75 flask with subconfluent Vero cells was infected
with YFV-17D-204-WHO (moi = 1). 24 h post-infection,
the culture medium was removed and replaced with
cysteine and methionine-free DMEM supplemented with
2% FCS, 2 mM glutamine and antibiotics for 1 h at 37 8C.
Then, 1 mCi of [35S] methionine and [35S] cysteine
(Promix Redivue, Amersham, Freiburg, Germany) was
added. After 48 h the cell culture supernatant was
harvested and radiolabeled virions were purified through
a 30% glycerol cushion as described above. Pelleted
virions were resuspended in TNE buffer containing the
mild, non-ionic detergent 0.5% n-octyl-h-D-glucopyrano-
side (Sigma, Deisenhofen, Germany) and a protease
inhibitor cocktail (Complete, Roche, Mannheim, Ger-
many), and sonicated three times for 10 s at 4 8C. The
preparation was cleared at 20,000  g for 1 h at 4 8C, then
150 Al was incubated with 1.5 Ag of scFv for 4 h at 4 8C.
Antigen–scFv complexes were immunoprecipitated by
addition of 1 Ag anti-His-tag antibody and 20 Al protein
G-coupled agarose beads (Santa Cruz Biotechnology, Santa
Cruz CA, USA) overnight on an overhead rotator at 4 8C.
IP was also performed with 1 Ag each of YFV-E-specific
mAbs 6538 and 6330, respectively, and 20 Al of protein G-
coupled agarose beads. As negative control, IP was also
performed with 1.5 Ag of an irrelevant scFv or with anti-
His-tag antibody alone. Samples were analyzed on a 12%
SDS–PAGE gel exposed to X-ray film.
Biotinylation of purified scFv-7A and competition ELISA
The purified scFv-7Awas biotinylated using the EZ-Link
NHS-LC-Biotin kit (Pierce Biotechnology, Rockford, IL,
USA) according to the manufacturer’s instructions and
dialyzed against PBS. 2 Ag of biotinylated scFv-7A was
mixed with increasing amounts of competitors (scFv or
mAbs) and incubated in a 96-well plate coated with purified
YFV-17D virions. Bound scFv-7Awas detected using HRP-
conjugated streptavidin (Pierce Biotechnology, Rockford,
IL, USA) diluted 1:10000. Competition was expressed as
the percentage of binding compared to biotinylated scFv-7A
alone.
Virus titration and neutralization assays
The ability of the antibody fragments or of human
sera to block YFV infection was tested in PRNT
S. Daffis et al. / Virology 337 (2005) 262–272 271using Vero or PS cells in a 6-well or 12-well format,
or in a 96-well microneutralization assay using Vero
cells.
(i) Virus titration using PS or Vero cells. Virus dilutions
and trypsinized PS cells (4.8  105 cells/well) were
added simultaneously to 12-well plates in a total
volume of 1 ml/well and incubated for 3 h at 37 8C.
The virus/cell mixture was overlaid with 1.6%
carboxymethylcellulose in L-15 medium. After incu-
bation for 4 days at 37 8C, cells were formalin fixed
and stained with 500 ng/ml naphtol blue black. Virus
was also titered on subconfluent Vero cells in 6-well
plates. After an incubation of 1 h at 37 8C, the
inoculum was removed, cells were washed once with
PBS and overlaid with 2% low-melt agarose. On day
5 after infection plaques were visualized with 0.005%
neutral red staining.
(ii) Plaque reduction neutralization assay (PRNT) using
PS or Vero cells. Serial twofold dilutions of recom-
binant antibodies starting at a final concentration of 10
Ag/ml were mixed with 100 plaque forming units
(pfu) virus in a total volume of 1 ml. After an
incubation period of 1 h at 37 8C, the virus/antibody
mixture was seeded in 12-well plates together with PS
cells and assayed for plaques as in (i). Human serum
samples were inactivated for 30 min at 56 8C and used
in serial twofold dilutions starting at 1:20. For PRNT
on Vero cells, the antibody/virus mixture was incu-
bated on subconfluent Vero cells and plaques were
assayed as in (i). The percentage of neutralization was
expressed as follows: 100  [(number of plaques
obtained with virus+scFv/number of plaques obtained
with virus only)  100].
(iii) Microneutralization assay with human sera. The 50%
tissue culture infective dose (TCID50) was determined
for the parental YFV-17D-204-WHO strain and for
the derived escape mutants 7A-10 and 7A-12. Each
virus was serially 10-fold diluted in DMEM without
FCS and 100 Al of each dilution (five replicates per
dilution) was incubated for 1 h at 37 8C on 2.5  104
subconfluent Vero cells per well of a pre-seeded 96-
well plate. The inoculum was removed and the cells
were washed three times with PBS. 100 Al of DMEM
with 2%FCS was added per well and the plate was
incubated at 37 8C. After 6 days, the cytopathic effect
was observed microscopically in each well and the
TCID50 was calculated using the Reed-Muench
formula. Human serum samples from YF patients
and 17D vaccinees were inactivated for 30 min at
56 8C and serially twofold diluted in DMEM without
FCS starting at a dilution of 1:20. The 50% end-point
dilution of each serum, corresponding to the dilution at
which 50% of wells were completely protected from
infection, was determined according to the Reed-
Muench formula.Selection of neutralization-resistant YFV-17D variants to
scFv-7A
In order to map the neutralizing epitopes on the E
protein, scFv-7A neutralization-resistant virus variants were
generated and partially sequenced. 100 pfu of YFV-17D-
204-WHO was incubated for 1 h at 37 8C with 95% of the
scFv-7A concentration which had been shown to completely
neutralize the inoculum (7 Ag/ml, see Results section). The
mixture was inoculated on Vero cells for 1 h at 37 8C in a 6-
well plate format. The inoculum was removed and replaced
with fresh medium supplemented with scFv-7A (7 Ag/ml).
Three days post-infection, 50 Al of the supernatant was
incubated with 1 ml DMEM/scFv-7A (7 Ag/ml) for 1 h at 37 8C
and inoculated on cells for 1 h at 37 8C. After removing the
inoculum, fresh medium containing scFv-7A (7 Ag/ml) was
added. This selection procedure was repeated twice. After the
third round of selection, escape mutants contained in the
supernatant were plaque purified. Twenty single clones were
propagated, plaque-titered and tested in PRNT with various
concentrations of scFv-7A as described above.
Sequencing of prM and E proteins
Viral RNA was isolated from infected cell culture
supernatants using the QIAamp viral RNA mini kit
(QIAGEN, Hilden, Germany). The E protein of the
neutralization escape mutants was amplified by RT/PCR
and sequenced as previously described (ter Meulen et al.,
2004). RT-PCR and sequencing of the M protein were
performed using a prM forward primer (5V-gatgttctgactgtg-
caatt-3V) and an M reverse primer (5V-ttcctccatgcaccccct-3V).
Wild-type YFV strains were first genotyped by amplify-
ing a 670 nucleotide fragment within the prM-E region
(Mutebi et al., 2001). The remainder of the E protein was
sequenced using two sets of primers that generate two
overlapping fragments. Primers were designed aligning
wild-type YFV sequences accessible in the GenBank and
designated EnvF1 (5V tgtgaagattaatgacaagtgcc), EnvF2 (5V
caatgataagtgcccgagc), EnvF3 (caggtcatggcacggttg), EnvR1
(ggattgacttcaattaggacttc), EnvR2 (5V cacctcaatcagcacttcatc),
NS1R1 (5Vcactattgatgcaagcttcacag) and NS1R2 (5V tctcca-
catttgagctctcg). Due to the sequence variability of the
envelope protein gene, the East/Central African strains were
amplified using primer combinations EnvF2/EnvR1 and
EnvF3/NS1R2, and the West African strains using EnvF1/
EnvR2 and EnvF3/NS1R1.Acknowledgments
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